Brown JR, et al. - Given the infrequent occurrence of major hemorrhage (MH) in ibrutinib (a Bruton tyrosine kinase inhibitor approved for treatment of various B-cell malignancies) clinical studies, researchers investigated its incidence and risk factors analyzing 15 ibrutinib clinical studies (N = 1768), including 4 randomised controlled trials (RCTs). Outcomes suggest no increased risk of MH with ibrutinib relative to comparators when corrected for treatment duration. Both ibrutinib- and comparator-treated patients displayed moderate associations between anticoagulants and/or antiplatelets (AC/AP) use and the risk of MH. This suggests that ibrutinib may not differentially alter the risk of MH with the use of these agents.